One- versus three-month DAPT after everolimus-eluting stent implantation in diabetic patients at high bleeding risk: results from the XIENCE Short DAPT programme
Authors' conclusion
Among HBR patients with DM undergoing PCI, 1-month DAPT, as compared to 3-month DAPT, was not associated with an excess of fatal or non-fatal MI and even reduced the occurrence of bleeding. These findings should be interpreted in the context of a predominantly stable patient population with low procedural complexity and may not be generalisable to higher-risk cases.
Study context
- Population
- Patients with high bleeding risk (HBR) undergoing percutaneous coronary intervention (PCI), with and without diabetes mellitus (DM)1,299 (38.8%) had DM · DM 1,299
- Participants
- 3,352 patients
- Exposure
- 1- versus 3-month DAPT
- Outcome
- Composite of:
- All-cause death
- Myocardial infarction (MI)
- Follow-up
- 1 year
Methodological detailspropensity score stratification
- Propensity score stratification
Main finding
As reported in the abstract
1-month DAPT vs 3-month DAPTAdjusted hazard ratio (95% CI)
DM patients
0.70(0.47–1.05)
non-DM patients
1.26(0.87–1.81)
Observational data: associations, not effects.
Secondary outcomes
Death or MI, DM vs non-DM · 1 year
BARC 2-5 bleeding, DM vs non-DM
Safety
| Outcome | adjHR (95% CI) | |
|---|---|---|
| BARC Type 2 to 5 bleeding (key secondary endpoint)1-month DAPTvs 3-month DAPTDM | 0.67 (0.45–1.01) | |
| BARC Type 2 to 5 bleeding (key secondary endpoint)1-month DAPTvs 3-month DAPTnon-DM | 0.78 (0.56–1.07) | |
| 0.512Adjusted hazard ratio (log scale) |
- Bleeding Academic Research Consortium (BARC) Type 2 to 5 bleeding (key secondary endpoint): p for interaction=0.973
Original publication
One- versus three-month DAPT after everolimus-eluting stent implantation in diabetic patients at high bleeding risk: results from the XIENCE Short DAPT programme. EuroIntervention. Published 16 June 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →